SCHOFIELD, Wis.--(BUSINESS WIRE)--PuraMed Bioscience, (OTC Bulletin Board:PMBS), a pharmaceutical company engaged in the development and marketing of a line of revolutionary, new, non-prescription medicines targeting major consumer health needs including the treatment of migraine headaches, insomnia and tension-type headaches, announced today that it has retained the services of Investor Awareness, Inc. (www.investorawareness.com) as its investor relations firm and North Shore Public Relations, Inc. (www.northshorepr.com) as its public relations firm. Investor Awareness and North Shore Public Relations will assist PuraMed Bioscience in creating outreach programs to increase visibility in the investment community, and news dissemination and media relations programs to help broaden awareness.
